Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002850 · ClinicalTrials.gov registry record · Phase 3
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
A Phase 3 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT00002850: Completed Phase 3 study, sponsored by Gary Morrow.
NCT00002850 is a Phase 3 study that has completed, run by Gary Morrow. The registered enrollment target is 212 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002850, a Phase 3 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
Primary Outcome
This study evaluated the impact of prophylactic antibiotics on the incidence of serious bacterial infections (SBIs) during the first 2 months of treatment in patients with newly diagnosed multiple myeloma. Patients with multiple myeloma receiving initial chemotherapy were randomized on a 1:1:1 basis to daily ciprofloxacin, trimethoprim-sulfamethoxazole, or observation and evaluated for SBI for the first 2 months of treatment.
Interventions
- DRUG ofloxacin
- DRUG ciprofloxacin
- DRUG 160 mg trimethoprim and 800 mg sulfamethoxazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 1997-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
What the finished NCT00002850 record still lists
NCT00002850 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 3 interventions - of which ofloxacin is the first listed.
NCT00002850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002850 about?
NCT00002850 is a clinical study titled "Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy". RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preve...
What is the current status of trial NCT00002850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 1997-03. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00002850?
The interventions under investigation include: ofloxacin (DRUG), ciprofloxacin (DRUG), 160 mg trimethoprim and 800 mg sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT00002850?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002850's enrollment target sits among peer trials
212 1335th of 2000 higher than 664 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia